{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-041613","form_type":"8-K","ticker":"STAA","cik":"0000718937","company_name":"STAAR SURGICAL CO","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.764324+00:00","generated_at":"2026-06-04T02:37:01.782058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"STAAR Surgical preliminary Q1 net sales >$77M; record US ICL sales of $5M, up 20% sequentially","bullets":["Preliminary Q1 2024 net sales in excess of $77M; US ICL sales hit record $5M, up ~20% sequentially.","EMEA ICL sales up ~11% YoY; APAC ICL sales up ~9% including ~10% growth in China.","Cash and investments ~$248M (Dec 2023: $232.4M); accounts receivable ~$70M (Dec 2023: $94.7M).","Fiscal 2024 net sales outlook now expected at higher end of $335M-$340M range.","Full Q1 results and 2024 outlook to be discussed on earnings call on/about May 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-041613","json":"https://secwatch.observer/filing/0000950170-24-041613.json","markdown":"https://secwatch.observer/filing/0000950170-24-041613.md","text":"https://secwatch.observer/filing/0000950170-24-041613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/718937/000095017024041613/0000950170-24-041613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/718937/000095017024041613/staa-20240404.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:37:01.782058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"333ac7ad511d54bab0b5cda2cdb475dbf49cb01b","claim":"STAAR SURGICAL CO reported first quarter ended March 29, 2024 results: revenue in excess of $77 million.","evidence_excerpt":"STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICLTM) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million, with U.S. ICL sales expected to be $5 million for the quarter.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024041613/0000950170-24-041613-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 29, 2024"},{"label":"Revenue","value":"in excess of $77 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}